Compare ARAY & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARAY | OVID |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.6M | 117.5M |
| IPO Year | 2006 | 2017 |
| Metric | ARAY | OVID |
|---|---|---|
| Price | $0.41 | $2.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $3.50 | $3.40 |
| AVG Volume (30 Days) | 887.9K | ★ 1.5M |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | 3.90 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $566,000.00 |
| Revenue This Year | N/A | $1,077.56 |
| Revenue Next Year | $4.58 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.24 |
| 52 Week High | $2.10 | $2.38 |
| Indicator | ARAY | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 22.29 | 67.31 |
| Support Level | N/A | $1.43 |
| Resistance Level | $0.63 | $2.01 |
| Average True Range (ATR) | 0.04 | 0.15 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 0.00 | 60.11 |
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.